- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05183256
Cohort of Inflammatory Bowel Disease Patient in Yeouido St. Mary's Hospital
December 20, 2021 updated by: Ilsoo Kim, MD, Yeouido St. Mary's Hospital
Development of the Cohort of the Patients With Inflammatory Bowel Disease in Yeouido St. Mary's Hospital
Pathologically Inflammatory bowel disease (IBD) is in chronic complex inflammatory gut pathological condition.
Although the etiology of IBD is unknown, gut microbiota alteration (dysbiosis) is considered a novel factor involved in the pathogenesis of IBD.
The aim of this study is to analyze gut microbiota in IBD patients.
Study Overview
Status
Recruiting
Conditions
Detailed Description
Inflammatory bowel disease (IBD) (Crohn's disease (CD) and ulcerative colitis (UC)) occurs worldwide with differences in epidemiology, etiology, and phenotype between regions.
Pathologically Inflammatory bowel disease (IBD) is in chronic complex inflammatory gut pathological condition.
Although the etiology of IBD is unknown, gut microbiota alteration (dysbiosis) is considered a novel factor involved in the pathogenesis of IBD.
The DNA of microbiota will be investigated with samples of stool, colon tissue.
The aim is to establish a cohort group for IBD (1), to make a database on cohort group characteristics such as endoscopic findings, disease severity, epidemiology, and prognosis (2), to analyze gut flora in IBD patients (3).
Study Type
Observational
Enrollment (Anticipated)
160
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ilsoo Kim, MD
- Phone Number: 82237791517
- Email: ilsookim86@gmail.com
Study Locations
-
-
-
Seoul, Korea, Republic of, 07241
- Recruiting
- Yeouido St. Mary's Hospital
-
Contact:
- Kyeongshin Hong
- Phone Number: 82237792021
- Email: sirb@cathoic.ac.kr
-
Principal Investigator:
- Ilsoo Kim, MD
-
Sub-Investigator:
- Han Hee Lee, MD, Ph.D
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 75 years (ADULT, OLDER_ADULT, CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
All consecutive patients with IBD, presented to division of gastroenterology, Yeouido St.Mary's hospital, will be asked to participate in this study.
Description
Inclusion Criteria:
The below 3 conditions must be met simultaneously.
- Patient who can voluntarily consent to this study.
- Patient who has inflammatory bowel disease.
- Patient who is aged less than 75 years.
Exclusion Criteria:
a patient meets any of the below conditions.
- If a patient has an IBD other than UC and CD.
- If a patient is vulnerable due to his/her position as an employee of Yeouido St.Mary's hospital or a medical student of the Catholic University of Korea.
- If a patient is pregnant.
- Foreign personal who cannot speak Korean.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with the remission of disease activity.
Time Frame: through study completion, an average of 2 year
|
Disease activity is assessed in a clinical, endoscopic, and biochemical way.
Each activity is determined by the Mayo score (in UC), Crohn's Disease Activity Index (in CD), Ulcerative Colitis Endoscopic Index of Severity (in UC), Simple Endoscopic Score for Crohn Disease (in CD), and biochemical findings (e.g.
fecal calprotectin).
|
through study completion, an average of 2 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ilsoo Kim, MD, Yeouido St. Mary's Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Park SH, Kim YJ, Rhee KH, Kim YH, Hong SN, Kim KH, Seo SI, Cha JM, Park SY, Jeong SK, Lee JH, Park H, Kim JS, Im JP, Yoon H, Kim SH, Jang J, Kim JH, Suh SO, Kim YK, Ye BD, Yang SK; Songpa-Kangdong Inflammatory Bowel Disease [SK-IBD] Study Group. A 30-year Trend Analysis in the Epidemiology of Inflammatory Bowel Disease in the Songpa-Kangdong District of Seoul, Korea in 1986-2015. J Crohns Colitis. 2019 Oct 28;13(11):1410-1417. doi: 10.1093/ecco-jcc/jjz081.
- Dalal SR, Chang EB. The microbial basis of inflammatory bowel diseases. J Clin Invest. 2014 Oct;124(10):4190-6. doi: 10.1172/JCI72330. Epub 2014 Aug 1.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
October 26, 2020
Primary Completion (ANTICIPATED)
May 31, 2025
Study Completion (ANTICIPATED)
August 25, 2025
Study Registration Dates
First Submitted
December 1, 2021
First Submitted That Met QC Criteria
December 20, 2021
First Posted (ACTUAL)
January 10, 2022
Study Record Updates
Last Update Posted (ACTUAL)
January 10, 2022
Last Update Submitted That Met QC Criteria
December 20, 2021
Last Verified
December 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SC20TISI0103
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammatory Bowel Diseases
-
Centre Hospitalier Universitaire, AmiensFunding from DGOS (PHRC IR 2013 and PRME)CompletedPediatric Inflammatory Bowel DiseaseFrance
-
University of Wisconsin, MadisonTerminatedInflammatory Bowel Disease (IBD)United States
-
Cedars-Sinai Medical CenterUnknownPediatric Inflammatory Bowel Disease
-
University of British ColumbiaCompletedInflammatory Bowel Disease 11Canada
-
University of ChicagoTerminatedInflammatory Bowel Disease (IBD)United States
-
Assiut UniversityNot yet recruitingIBD-Inflammatory Bowel Disease
-
University of Wisconsin, MadisonCompletedInflammatory Bowel Disease (IBD)United States
-
Hull University Teaching Hospitals NHS TrustWellcome/EPSRC Centre for Interventional and Surgical Sciences, University...RecruitingInflammatory Bowel Disease 1United Kingdom
-
Icahn School of Medicine at Mount SinaiNorthwestern University; The Cleveland Clinic; University of California, Davis; RxHealt...RecruitingInflammatory Bowel Disease (IBD)United States
-
Nemours Children's ClinicNASPGHAN FoundationCompletedInflammatory Bowel Disease (IBD)United States